CN106389575A - 一种复合葛根解酒胶囊及其制备方法 - Google Patents
一种复合葛根解酒胶囊及其制备方法 Download PDFInfo
- Publication number
- CN106389575A CN106389575A CN201610789348.2A CN201610789348A CN106389575A CN 106389575 A CN106389575 A CN 106389575A CN 201610789348 A CN201610789348 A CN 201610789348A CN 106389575 A CN106389575 A CN 106389575A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix puerariae
- capsule
- compound
- taurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 56
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000002075 anti-alcohol Effects 0.000 title abstract description 7
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 46
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 42
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 40
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 210000000582 semen Anatomy 0.000 claims abstract description 25
- 229960003080 taurine Drugs 0.000 claims abstract description 23
- 239000001530 fumaric acid Substances 0.000 claims abstract description 21
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229930195712 glutamate Natural products 0.000 claims abstract description 20
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 18
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 18
- 229940046240 glucomannan Drugs 0.000 claims abstract description 18
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims description 30
- 239000003814 drug Substances 0.000 claims description 27
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 22
- 235000008584 Hovenia dulcis Nutrition 0.000 claims description 21
- 244000010000 Hovenia dulcis Species 0.000 claims description 21
- 235000013399 edible fruits Nutrition 0.000 claims description 21
- 229930003944 flavone Natural products 0.000 claims description 21
- 235000011949 flavones Nutrition 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 238000004659 sterilization and disinfection Methods 0.000 claims description 21
- 238000011049 filling Methods 0.000 claims description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 14
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 14
- 150000002212 flavone derivatives Chemical class 0.000 claims description 13
- 239000001384 succinic acid Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 150000002213 flavones Chemical class 0.000 claims description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 238000005429 filling process Methods 0.000 claims description 6
- 238000007689 inspection Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005498 polishing Methods 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 244000182067 Fraxinus ornus Species 0.000 claims description 2
- 235000002917 Fraxinus ornus Nutrition 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 48
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 7
- 241000132012 Atractylodes Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 229940069445 licorice extract Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 229940049906 glutamate Drugs 0.000 description 14
- 210000002784 stomach Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 229920000057 Mannan Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NYBPFKCUSHIQDN-HYUTVRSWSA-N (2s)-2-aminopentanedioic acid;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)[C@@H](N)CCC(O)=O NYBPFKCUSHIQDN-HYUTVRSWSA-N 0.000 description 2
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 244000202052 Poncirus trifoliata Species 0.000 description 2
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical class CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000008539 L-glutamic acids Chemical class 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003628 tricarboxylic acids Chemical group 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种复合葛根解酒胶囊及其制备方法,由如下重量百分比的原料组成:葛根提取物27‑40%、枳椇子提取物3‑15%、甘草提取物1‑5%、决明子提取物0.5‑2.5%、山楂提取物5‑12%、茯苓提取物4‑7%、白术提取物3‑6%、牛磺酸0.5‑2%、VC 0.5‑2%、VB10.1‑0.15%、VB60.1‑0.15%、琥珀酸0.5‑2%、富马酸0.05‑0.55%、谷氨酸盐0.5‑2%、葡甘露聚糖25‑36%,其中,葛根提取物的总黄酮含量不小于50%。产品充分利用葛根等原料的生物、化学解酒功能,同时加入葡甘露聚糖,利用其超强吸附酒精的作用进行物理解酒,使解酒胶囊兼具生物化学解酒和物理吸附解酒的双重功效。
Description
技术领域
本发明涉及食品及药品加工技术领域,特别是一种复合葛根解酒胶囊及其制备方法。
背景技术
我国酒文化源远流长,酒桌文化也异常丰富,在商务、社交活动中,酒是不可或缺的元素。2014年,全国酿酒行业规模以上企业完成酿酒总产量7528.27万吨,同比增长0.87%,累计完成产品销售收入8778.05亿元,同比增长5.85%。我国已经形成了稳定的8000亿元级的饮酒市场。近年来,饮酒人数一直呈增长趋势,据统计,我国目前有6亿酒民,其中65%的人属不健康饮酒人群,主要为饮酒过量,80%的人认为,对于生活中饮酒过量的现象无法避免。饮酒过量会引起头痛、晕眩、神经模糊、呕吐等症状,严重的会对肝胃、脾等内脏器官造成伤害,引起机体生理紊乱,甚至影响家庭幸福和社会安定。随着人们保健意识的增强,酒民及其家人对解酒产品的渴望越来越强烈。
目前,市场上的解酒药大多采用化学成分,虽然具有一定的解酒功效,然后却无法避免化学成分对人体的二次伤害;同时,目前市场上的解酒药大多仅仅采用化学解酒方式,方式单一,在解酒功效上不足。
发明内容
本发明提供一种复合葛根解酒胶囊及其制备方法,本发明充分利用了葛根、枳椇子、甘草、决明子、山楂、茯苓、白术等天然药材及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸谷氨酸盐等原料中有效成分的生理及化学解酒作用以及魔芋中葡甘露聚糖超强吸附酒液的物理解酒作用,兼具生物化学解酒和物理吸附解酒的双重功效。
本发明一种复合葛根解酒胶囊所采用的技术方案是:
一种复合葛根解酒胶囊,由如下重量百分比的原料组成:
葛根提取物27-40%、枳椇子提取物3-15%、甘草提取物1-5%、决明子提取物0.5-2.5%、山楂提取物5-12%、茯苓提取物4-7%、白术提取物3-6%、牛磺酸0.5-2%、VC 0.5-2%、VB10.1-0.15%、VB60.1-0.15%、琥珀酸0.5-2%、富马酸0.05-0.55%、谷氨酸盐0.5-2%、葡甘露聚糖25-36%;
其中,葛根提取物的总黄酮含量不小于50%。
一种复合葛根解酒胶囊,由如下重量百分比的原料组成:
葛根提取物32-35%、枳椇子提取物8-10%、甘草提取物2-4%、决明子提取物1-2%、山楂提取物8-9%、茯苓提取物5-6%、白术提取物4-5%、牛磺酸1-1.5%、VC 1-1.5%、VB10.05-0.1%、VB60.05-0.1%、琥珀酸1-1.5%、富马酸0.1-0.5%、谷氨酸盐1-1.5%、葡甘露聚糖29-36%;
其中,葛根提取物的总黄酮含量不小于50%。
一种复合葛根解酒胶囊,由如下重量百分比的原料组成:
葛根提取物33%、枳椇子提取物9%、甘草提取物3%、决明子提取物1.5%、山楂提取物8.5%、茯苓提取物5.5%、白术提取物4.5%、牛磺酸1.25%、VC 1.25%、VB1 0.075%、VB6 0.075%、琥珀酸1.75%、富马酸0.3%、谷氨酸盐1.25%、葡甘露聚糖29.05%;
其中,葛根提取物的总黄酮含量不小于50%。
一种复合葛根解酒胶囊,由如下重量百分比的原料组成:
葛根提取物32%、枳椇子提取物8%、甘草提取物2%、决明子提取物1%、山楂提取物8%、茯苓提取物5%、白术提取物4%、牛磺酸1%、VC 1%、VB1 0.1%、VB6 0.1%、琥珀酸1.5%、富马酸0.5%、谷氨酸盐1.5%、葡甘露聚糖34.3%;
其中,葛根提取物的总黄酮含量不小于50%。
一种复合葛根解酒胶囊的制备方法,包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎、经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅 料粉末予以清洁;
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器中,既得成品。
在步骤3中,将称量好的原料投入高速搅拌机中,在常温常压条件下搅拌10~20min,使原料混合均匀。
在步骤4中,对混合均匀的产品,采用臭氧结合紫外灭菌的方式进行灭菌处理。
在步骤7中,在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
本发明的有益效果是:本产品饮酒前预先服用能阻隔或减少酒精进入胃和肝脏的血管内,让酒精与胃及肝脏隔离免受酒精伤害。饮酒中及饮酒后会服用可以将残余在胃及肠内的酒精吸收、分解,阻隔酒精继续被吸进血管内,立即舒缓酒醉,迅速恢复清醒。本品具有良好的解酒作用。
具体实施方式
下面就具体实施方式对本发明进行详细说明。
一种复合葛根解酒胶囊,由如下重量百分比的原料组成:
葛根提取物27-40%、枳椇子提取物3-15%、甘草提取物1-5%、决明子提取物0.5-2.5%、山楂提取物5-12%、茯苓提取物4-7%、白术提取物3-6%、牛磺酸0.5-2%、VC 0.5-2%、VB1 0.1-0.15%、VB6 0.1-0.15%、琥珀酸0.5-2%、富马酸0.05-0.55%、谷氨酸盐0.5-2%、葡甘露聚糖25-36%;
其中,葛根提取物的总黄酮含量不小于50%。
本发明以葛根提取物(总黄酮≧50%)、枳椇子提取物、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物为主要原料,在这个基础上再配入人体所需的营养成分,如牛磺酸、VC、VB1、VB6及琥珀酸、富马酸谷氨酸盐等,利用其生物、化学解酒功能,同时加入葡甘露聚糖,利用其超强吸附酒精的作用进行物理解酒,就能在人们饮酒时发挥高效解酒性能和对人体起到全面的保护作用,使解酒胶囊兼具生物化学解酒和物理吸附解酒的双重功效。
主要原辅料功效:
葛根的有效成份主要为黄酮类化合物。《本草纲目》载,葛根具清热祛火,生津止渴,解酒醒脾等作用。葛根中富含多达13种异黄酮类物质,包括葛根素、大豆甙等有效活性成份,具有清火、排毒、解酒、抗癌、降血脂、降血压之功效。大豆甙可以分解乙醇成分,减少乙醇对大脑的伤害,减轻酒精对肠胃的刺激,促进新陈代谢,促使血液排掉酒精毒素。
枳椇子,又名拐枣,《本草纲目》中曾记载“其枝、叶,止呕逆,解酒毒,辟虫毒”。枳椇子含葡萄糖、果糖、过氧化物酶等成分,有抗脂质过氧化、保肝、解酒毒、及抑制中枢神经等方面的药理作用。
山楂含山楂酸等多种有机酸,味酸甘,并含解脂酶,入胃后,能增强酶的作用,促进肉食消化,有助于胆固醇转化。
决明子具有保肝护肝,润肠通便,降脂减肥的功能。可以促进新陈代谢,加速酒精代谢,减少对肠胃刺激;
甘草味甘甜,性平和,入心、脾、肺、胃四经。可泻火解毒、缓急止痛;炙用偏温,能散表寒、补中益气。此外,甘草还善于调和药性,解百药之毒。甘草味甘甜,性平和,入心、脾、肺、胃四经。生用偏凉,可泻火解毒、缓急止痛;炙用偏温,能散表寒、补中益气。此外,甘草还善于调和药性,解百药之毒。
茯苓利水渗湿,而药性平和,可以通利小便使酒气自小便排出。
白术健脾益气、燥湿利水、止呕吐,消食导滞。
牛磺酸强肝利胆解热抗炎
维生素C用于维护中枢神经体系,肝脏和激素活性组织的抗氧化系统,维护产生抗压激素的肾上腺皮层。
琥珀酸和富马酸能激活三羧酸第二部分循环,在线粒体的氧化过程中产生活化作用,发挥更强的抗毒作用。加速毒性物质分解成乙酸,二氧化碳和水。
葡萄糖(右旋糖)在肝脏细胞液中和用于乙醇分解的NAD细胞液共同产生作用,迅速氧化,导致反应所需的NAD细胞液不足,减缓乙醇氧化过程。
L-谷氨酸盐,可以加速线粒体-苹果酸-天(门)冬氨酸盐的传送。
葡甘露聚糖能吸附其本身质量的200倍而不会被胃内的酶所消化,粉状的葡甘露聚糖在体内吸收羟基化液体如水、酒精、水溶性脂肪酸和碳水化合物等,并溶胀及形成胶状物质。随后,缓慢地通过整 个小肠,到达大肠和结肠。由于葡甘露聚糖的粘度和胶体特性,有助它能附在肠壁上,形成一层屏障,阻碍肠绒毛吸收消化食物,故能减少酒精的吸收。
实施例1
本发明的一种复合葛根解酒胶囊,由下述重量百分比的原料组成:
葛根提取物37%、枳椇子提取物13%、甘草提取物3%、决明子提取物0.5%、山楂提取物10%、茯苓提取物7%、白术提取物3%、牛磺酸0.5%、VC 0.5%、VB10.1%、VB60.1%、琥珀酸0.5%、富马酸0.05%、谷氨酸盐0.5%、葡甘露聚糖25.25%;
其中,葛根提取物的总黄酮含量不小于50%。
本发明的一种复合葛根解酒胶囊在制作时,包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎、经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机中,在常温常压条件下搅拌10min,使原料混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;灭菌处理是采用臭氧结合紫外灭菌的方式进行的灭菌处理。
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅料粉末予以清洁;具体来说,是在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器中,既得成品。
实施例2
本发明的一种复合葛根解酒胶囊,由下述重量百分比的原料组成:
葛根提取物33%、枳椇子提取物9%、甘草提取物3%、决明子提取物1.5%、山楂提取物8.5%、茯苓提取物5.5%、白术提取物4.5%、牛磺酸1.25%、VC 1.25%、VB1 0.075%、VB6 0.075%、琥珀酸1.75%、富马酸0.3%、谷氨酸盐1.25%、葡甘露聚糖29.05%;
其中,葛根提取物的总黄酮含量不小于50%。
本发明的一种复合葛根解酒胶囊在制作时,包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎、经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机中,在常温常压条件下搅拌20min,使原料混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;灭菌处理是采用臭氧灭菌结合紫外灭菌的方式进行的灭菌处理。
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅料粉末予以清洁;具体来说,是在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器中,既得成品。
实施例3
本发明的一种复合葛根解酒胶囊,由下述重量百分比的原料组成:
葛根提取物32%、枳椇子提取物8%、甘草提取物2%、决明子提取物1%、山楂提取物8%、茯苓提取物5%、白术提取物4%、牛磺酸1%、VC 1%、VB1 0.1%、VB6 0.1%、琥珀酸1.5%、富马酸0.5%、谷氨酸盐1.5%、葡甘露聚糖34.3%;
其中,葛根提取物的总黄酮含量不小于50%。
本发明的一种复合葛根解酒胶囊在制作时,包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎、经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机中,在常温常压条件下搅拌20min,使原料混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;灭菌处理是采用臭氧灭菌结合紫外灭菌的方式进行的灭菌处理。
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅料粉末予以清洁;具体来说,是在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器中,既得成品。
实施例4
本发明的一种复合葛根解酒胶囊,由下述重量百分比的原料组成:
葛根提取物32%、枳椇子提取物8%、甘草提取物2%、决明子 提取物1%、山楂提取物8%、茯苓提取物5%、白术提取物4%、牛磺酸1%、VC 1%、VB1 0.1%、VB6 0.1%、琥珀酸1.5%、富马酸0.5%、谷氨酸盐1.5%、葡甘露聚糖34%;
其中,葛根提取物的总黄酮含量不小于50%。
本发明的一种复合葛根解酒胶囊在制作时,包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎、经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机中,在常温常压条件下搅拌15min,使原料混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;灭菌处理是采用臭氧灭菌结合紫外灭菌的方式进行的灭菌处理。
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅料粉末予以清洁;具体来说,是在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器。
Claims (8)
1.一种复合葛根解酒胶囊,其特征在于,由如下重量百分比的原料组成:
葛根提取物27-40%、枳椇子提取物3-15%、甘草提取物1-5%、决明子提取物0.5-2.5%、山楂提取物5-12%、茯苓提取物4-7%、白术提取物3-6%、牛磺酸0.5-2%、VC 0.5-2%、VB1 0.1-0.15%、VB6 0.1-0.15%、琥珀酸0.5-2%、富马酸0.05-0.55%、谷氨酸盐0.5-2%、葡甘露聚糖25-36%;
其中,葛根提取物的总黄酮含量不小于50%。
2.根据权利要求1所述的一种复合葛根解酒胶囊,其特征在于,由如下重量百分比的原料组成:
葛根提取物32-35%、枳椇子提取物8-10%、甘草提取物2-4%、决明子提取物1-2%、山楂提取物8-9%、茯苓提取物5-6%、白术提取物4-5%、牛磺酸1-1.5%、VC 1-1.5%、VB10.05-0.1%、VB6 0.05-0.1%、琥珀酸1-1.5%、富马酸0.1-0.5%、谷氨酸盐1-1.5%、葡甘露聚糖29-36%;
其中,葛根提取物的总黄酮含量不小于50%。
3.根据权利要求1所述的一种复合葛根解酒胶囊,其特征在于,由如下重量百分比的原料组成:
葛根提取物33%、枳椇子提取物9%、甘草提取物3%、决明子提取物1.5%、山楂提取物8.5%、茯苓提取物5.5%、白术提取物4.5%、牛磺酸1.25%、VC 1.25%、VB1 0.075%、VB60.075%、琥珀酸1.75%、富马酸0.3%、谷氨酸盐1.25%、葡甘露聚糖29.05%;
其中,葛根提取物的总黄酮含量不小于50%。
4.根据权利要求1所述的一种复合葛根解酒胶囊,其特征在于,由如下重量百分比的原料组成:
葛根提取物32%、枳椇子提取物8%、甘草提取物2%、决明子提取物1%、山楂提取物8%、茯苓提取物5%、白术提取物4%、牛磺酸1%、VC 1%、VB1 0.1%、VB6 0.1%、琥珀酸1.5%、富马酸0.5%、谷氨酸盐1.5%、葡甘露聚糖34.3%;
其中,葛根提取物的总黄酮含量不小于50%。
5.一种复合葛根解酒胶囊的制备方法,其特征在于:包括以下步骤:
步骤1:将葛根提取物(总黄酮≧50%)、枳椇子提取、甘草提取物、决明子提取物、山楂提取物、茯苓提取物、白术提取物及牛磺酸、VC、VB1、VB6、琥珀酸、富马酸、谷氨酸盐、葡甘露聚糖分别粉碎,经过70~90目的分子筛过滤,随后备用;
步骤2:称重:将以上各种原料依配方精确称量;
步骤3:混料:将称量好的原料置入高速搅拌机混合均匀;
步骤4:灭菌:对混合均匀的产品进行灭菌处理;
步骤5:填充:经灭菌处理的药品,直接填充到胶囊壳中;
步骤6:封口:对填充完成的胶囊封口;
步骤7:整理与抛光:对填充后的胶囊表面黏有少量药物或者辅料粉末予以清洁;
步骤8:质检:对产品进行理化及卫生学检测;
步骤9:包装:检验合格的产品用铝塑包装机包装或者装入容器中,既得成品。
6.根据权利要求5所述的一种复合葛根解酒胶囊的制备方法,其特征在于:在步骤3中,将称量好的原料投入高速搅拌机中,在常温常压条件下搅拌10~20min,使原料混合均匀。
7.根据权利要求5所述的一种复合葛根解酒胶囊的制备方法,其特征在于:在步骤4中,对混合均匀的产品,采用臭氧结合紫外灭菌的方式进行灭菌处理。
8.根据权利要求5所述的一种复合葛根解酒胶囊的制备方法,其特征在于:在步骤7中,在超净工作台用灭菌纱布轻轻搓使之光亮,对填充过程中在胶囊表面留下的少量药物或者辅料粉末进行清理。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610789348.2A CN106389575A (zh) | 2016-08-31 | 2016-08-31 | 一种复合葛根解酒胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610789348.2A CN106389575A (zh) | 2016-08-31 | 2016-08-31 | 一种复合葛根解酒胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106389575A true CN106389575A (zh) | 2017-02-15 |
Family
ID=58000698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610789348.2A Pending CN106389575A (zh) | 2016-08-31 | 2016-08-31 | 一种复合葛根解酒胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106389575A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110074243A (zh) * | 2019-04-29 | 2019-08-02 | 海南路易丹尼生物科技有限公司 | 一种具有解酒和保护肝脏功能的压片糖果 |
-
2016
- 2016-08-31 CN CN201610789348.2A patent/CN106389575A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110074243A (zh) * | 2019-04-29 | 2019-08-02 | 海南路易丹尼生物科技有限公司 | 一种具有解酒和保护肝脏功能的压片糖果 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102511869B (zh) | 红枣生姜浓浆 | |
CN102038057B (zh) | 一种滋养解酒冰茶 | |
CN101869235A (zh) | 一种蜂蜜膏的配方及制备方法 | |
CN102511867B (zh) | 红枣阿胶枸杞浓浆及其生产工艺 | |
CN105727081A (zh) | 一种用于治疗痛风的保健品组合物 | |
CN106689933A (zh) | 一种富含天然成分提取物的解酒护肝饮料及其制备方法 | |
KR20020022342A (ko) | 스트레스 예방 및 치료를 위한 항스트레스제 조성물 | |
CN108552491A (zh) | 具有降三高病症功能的复方醋蛋液及其制备方法 | |
CN104000195B (zh) | 清肺排毒口服液及其生产方法 | |
CN101978892B (zh) | 一种竹醋解酒饮料及其制备方法 | |
KR101483255B1 (ko) | 총백을 이용한 기능성 한방차 및 그 제조방법 | |
KR101452884B1 (ko) | 총백을 이용한 기능성 한방차 및 그 제조방법 | |
CN103989173B (zh) | 养肺护肺排毒健康食品及其生产方法 | |
CN106822622A (zh) | 一种解酒护肝口服组合物及其制备方法 | |
KR20100077781A (ko) | 발기부전에 효과적인 기능성 분말의 제조 방법, 이에 의한 기능성 분말을 포함하는 기능성 보조식품 | |
CN106389575A (zh) | 一种复合葛根解酒胶囊及其制备方法 | |
CN114767826B (zh) | 一种醒酒护肝组合物、具有醒酒护肝功效的饮料及其制备方法 | |
CN102559460A (zh) | 一种养生酒及其制备方法 | |
CN1142785C (zh) | 抗疲劳胶囊 | |
CN101085967A (zh) | 玫瑰花酒 | |
CN115089661A (zh) | 辅助调节内分泌代谢并抗癌防癌的人参组合物的应用 | |
CN107772330A (zh) | 一种复方无花果冻干粉含片 | |
CN102511879B (zh) | 红枣龟苓浓浆 | |
CN108967757A (zh) | 一种红枣生姜浓浆生产工艺 | |
CN108634300A (zh) | 一种具有辅助降血糖功能的保健品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170215 |